VR Adviser LLC trimmed its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 32.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,952,371 shares of the company's stock after selling 1,447,629 shares during the period. 4D Molecular Therapeutics comprises 1.1% of VR Adviser LLC's investment portfolio, making the stock its 21st largest position. VR Adviser LLC owned 6.39% of 4D Molecular Therapeutics worth $16,445,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $50,000. PNC Financial Services Group Inc. increased its stake in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after purchasing an additional 3,630 shares during the period. Daiwa Securities Group Inc. increased its stake in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after purchasing an additional 9,737 shares during the period. Finally, Velan Capital Investment Management LP purchased a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $56,000. 99.27% of the stock is owned by hedge funds and other institutional investors.
4D Molecular Therapeutics Stock Performance
Shares of FDMT stock opened at $3.80 on Tuesday. The firm has a market cap of $176.04 million, a P/E ratio of -1.33 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The business's 50 day moving average price is $3.29 and its 200-day moving average price is $5.05.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). As a group, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.
Wall Street Analyst Weigh In
FDMT has been the topic of a number of analyst reports. Royal Bank of Canada decreased their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday, May 10th. The Goldman Sachs Group decreased their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Bank of America decreased their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.56.
View Our Latest Analysis on FDMT
4D Molecular Therapeutics Profile
(
Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Further Reading
Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
